Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change
18/09/26	CAD 0.1050	0.00%
17/09/26	CAD 0.1050	0.00%
16/09/26	CAD 0.1050	+5.00%
15/09/26	CAD 0.1000	-9.09%
14/09/26	CAD 0.1100	-18.52%

Delayed Quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1050CAD

Average target price

1.000CAD

Spread / Average Target

+852.38%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. 05:18:34 19/09/26 am AEST			5-day change	1st Jan Change
0.1050 ^CAD	0.00%		-25.00%	-19.23%

11/09	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI

Market Cap	39.65M 28.31M 24.68M 23.31M 21.16M 2.72B 39.82M 279M 108M 1.38B 106M 104M 4.44B	P/E 2026 *	-4.2x	P/E 2027 *	-3.5x
Enterprise Value	39.65M 28.31M 24.68M 23.31M 21.16M 2.72B 39.82M 279M 108M 1.38B 106M 104M 4.44B	EV / Sales 2026 *	-	EV / Sales 2027 *	15.9x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
Toronto S.E.	SVA	Delayed
OTC Markets	SEOVF	Delayed
Xetra	PSH0	Delayed
Tradegate	PSH0	Real-time
Deutsche Boerse AG	PSH0	Delayed
Boerse Muenchen	PSH0	Real-time
Börse Stuttgart	PSH0	Delayed

11/09	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI
17/06	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
12/06	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
23/04	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
14/03	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
05/03	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
20/12	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
19/12	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
13/11	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/09/25	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
16/09/25	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
10/07/25	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT

Sernova Stock Toronto S.E.

Stocks

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

Valuation: Sernova

Chart: Sernova

Latest news: Sernova

Press Releases: Sernova

News in other languages: Sernova

Quotes and Performance

Price Extremes

Managers and Directors: Sernova

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

12/09	Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.	NE
10/09	Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference	AQ
08/09	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ
21/07	A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up	AQ
17/06	Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy	AQ

15/09/23	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/09/23	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/05/23	AstraZeneca : accord de recherche avec le canadien Sernova
03/05/23	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/04/23	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

1 week	-22.22%
Current month	-4.55%
3 months	-34.38%
6 months	-30.00%
Current year	-19.23%

1 week	0.1	0.14
1 month	0.1	0.15
3 years	0.1	0.83
5 years	0.1	2.22
10 years	0.1	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	58	12/08/2024
James Parsons DFI	Director of Finance/CFO	60	11/10/2024
David Burke IRC	Investor Relations Contact	-	11/10/2024

Director	Title	Age	Since
James Parsons BRD	Director/Board Member	60	19/04/2012
Steven Sangha BRD	Director/Board Member	-	24/04/2023
David Paterson BRD	Director/Board Member	-	01/09/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA	0.00%	-25.00%	-41.67%	-86.54%	28.34M
STRYKER CORPORATION	-1.79%	-0.16%	-27.19%	-6.17%	107B
SMITH & NEPHEW PLC	-0.77%	+1.88%	-24.84%	-2.00%	11.63B
GLAUKOS CORPORATION	+1.48%	-2.06%	+90.83%	+116.88%	9.52B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.75%	+2.06%	-52.06%	-71.12%	3.99B
DOUBLE MEDICAL TECHNOLOGY INC.	+0.39%	+0.36%	-28.86%	+21.76%	2.33B
INSPIRE MEDICAL SYSTEMS, INC.	+5.55%	+5.18%	-7.94%	-63.46%	2.1B
INSIGHT LIFETECH CO., LTD.	+4.97%	+4.82%	-	-	1.84B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+0.72%	+1.95%	-20.50%	-29.27%	1.52B
Average	+1.41%	+1.47%	-14.03%	-14.99%	17.55B
Weighted average by Cap.	-1.15%	+0.07%	-19.27%	+0.09%

	2026 *	2027 *
Net sales	-	2.5M 1.78M 1.56M 1.47M 1.33M 171M 2.51M 17.6M 6.79M 87.06M 6.7M 6.56M 280M
Net income	-11.3M -8.07M -7.03M -6.64M -6.03M -774M -11.35M -79.56M -30.7M -394M -30.3M -29.63M -1.27B	-13.9M -9.92M -8.65M -8.17M -7.42M -952M -13.96M -97.86M -37.77M -484M -37.27M -36.45M -1.56B
Net Debt	-	-